Cangrelor PK/PD analysis in post‐operative neonatal cardiac patients at risk for thrombosis

Essentials An optimal therapeutic strategy has yet to be established to prevent early shunt thrombosis. A phase 1 study of cangrelor was performed in neonates after palliation of congenital heart disease. PD endpoint of >90% platelet inhibition in 60% of patients was achieved at 0.5 µg/kg/min dos...

Ausführliche Beschreibung